This is a non-core endpoint: only basic statistics are computed.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Medicine purchases: ATC
L04AB05
1 out of 7 registries used, show all original rules.
478
Check minimum number of events
Min. number of events
3
478
Include endpoints None
478
Remove individuals based on genotype QC
458
RX_L04AB05
Control definitions
Control exclude
RX_L04AB
Extra metadata
First used in FinnGen datafreeze
DF4
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Certolizumab pegol
based on the number of shared cases.
Broader endpoints:
- Tumor necrosis factor alpha inhibitors
- Biological medication for rheuma
- ILD medications: immunosuppressive drugs
- ILD medications
- Any reimbursement code in KELA
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 458 | 359 | 99 |
| Unadjusted prevalence (%) | 0.11 | 0.16 | 0.05 |
| Mean age at first event (years) | 45.46 | 44.34 | 49.51 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: RX_L04AB05 – Certolizumab pegol
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Certolizumab pegol
↥Endpoint not on priority list, no data to show.